Register

COURSE DESCRIPTION:
Please join us for Thrombolytics for Acute Ischemic Stroke: Have We Found the Right (Tenecte)Plase in Therapy? with Karen Berger, Pharm.D., FASHP, FCCM, BCPS, BCCCP. Dr. Berger will describe the pharmacologic management of ischemic stroke and discuss key challenges in the implementation of tenecteplase for stroke management, among other aspects of this topic.

TARGET AUDIENCE:
Internal Medicine Physicians, Pharmacists, Physician Assistants, Residents, Advanced Practice Registered Nurses, and all other interested healthcare providers

LEARNING OBJECTIVES:

• Describe the pharmacologic management of ischemic stroke.
• Compare and contrast thrombolytics for the management of acute ischemic stroke.
• Discuss recent articles about the potential place in therapy for tenecteplase for acute ischemic stroke.
• Discuss key challenges in the implementation of tenecteplase for stroke management.
   

FACULTY AND DISCLOSURES:

Karen Berger, Pharm.D., FASHP, FCCM, BCPS, BCCCP
Neurocritical Care Clinical Pharmacist
Boca Raton Regional Hospital
Baptist Health South Florida
Boca Raton, Florida

Karen Berger, Pharm.D., FASHP, FCCM, BCPS, BCCCP, faculty for this educational activity, is on the speaker’s bureau for CSL Behring Kcentra® and has indicated that the presentation will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated. 

John Rubin, M.D., director for this educational event, owns stock in AstraZeneca and Bristol Myers Squibb. He has indicated that the presentation or discussion will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.  

Kenneth Rosenthal, M.D., FACG, moderator for this educational event, indicated that he is on the Speaker’s Bureau for AbbVie, Inc. All of the relevant financial relationships listed for this individual has been mitigated. 

Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships to disclose with ineligible companies.*

*Ineligible companies – Companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.
Disclosure Policy and Disclaimer

ACCREDITATION STATEMENTS AND CREDITS

Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.

Baptist Health South Florida designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.   

This activity has been approved for 1 credit hour, CE Broker Course #20-855841, by the Florida Boards of Medicine, Podiatry, Dentistry, Osteopathic Medicine and Physician Assistants.  

This activity has also been approved for 1 credit for Nurse Practitioners, Nurses, Pharmacists and Pharmacy Techs, Athletic Trainers. Baptist Health South Florida CE Broker Provider #50-182.